Please login to the form below
Triple negative breast cancer
This page shows the latest Triple negative breast cancer news and features for those working in and with pharma, biotech and healthcare.
Gilead announces positive new data for Trodelvy in metastatic breast cancer
Trodelvy is currently approved in more than 40 countries for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or ... help bring Trodelvy to more people living with
Latest news
-
Merck’s Keytruda receives NICE recommendation as breast cancer treatment option
Specifically, NICE’s recommends Keytruda as an option with chemotherapy for neoadjuvant, and alone as adjuvant treatment after surgery for patients with early triple-negative or locally advanced breast cancer. ... The decision marks the first time
-
Gilead’s Trodelvy granted FDA priority review for metastatic breast cancer
Commenting on the FDA’s decision, Bill Grossman, senior vice president, therapeutic area head, Gilead Oncology, said: “Trodelvy has already changed the treatment landscape in second-line metastatic triple-negative breast ... Trodelvy is approved in
-
Merck’s Keytruda combined with chemotherapy could benefit thousands of breast cancer patients
Women diagnosed with cases of early triple-negative breast cancer (TNBC) where the disease had not progressed beyond the breast and lymph nodes – markers in stage 2 and 3 – were treated ... pre-operative chemotherapy increases the treatment response
-
Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
European patients with metastatic triple-negative breast cancer can now receive the antibody-drug conjugate as second-line monotherapy. ... The therapy is now indicated as monotherapy for the treatment of adults with unresectable (cannot be removed by
-
Gilead sales rise by 13%, buoyed by anti-COVID-19 drug Veklury
O’Day also focused on the company’s oncology drugs and said: “Our marketed portfolio continues to expand with four new country approvals for Trodelvy for metastatic triple-negative breast cancer, ... Sales of Tecartus (brexucabtagene autoleucel)
More from news
Approximately 10 fully matching, plus 82 partially matching documents found.
Latest Intelligence
-
The Age of Diversity, Equality and Inclusion
Take a trial for triple negative breast cancer, for example, that was done predominantly on white women when it disproportionately affects black women.
-
Patient diversity in clinical trials needs to be centre stage
For example, a few years back we created clinical trial advertising materials for a Triple Negative Breast Cancer study project and, as the condition adversely impacts the black population, we made ... opportunities.”. A blood cancer charity recently
-
Cortellis Drugs to Watch in 2020 report
9. Immunomedic’s sacituzumab govitecan initial target market is metastatic triple negative breast cancer in patients who have failed at least two prior therapies. ... It is approved in the US for the treatment of unresectable or metastatic
-
Deal Watch January 2018
The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... Tucatinib is currently being
-
Deal Watch February 2017
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. ... Acquisition - company. 2, 475. Immunomedics/ Seattle Genetics. IMMU-132 (sacituzumab govitecan), an antibody drug conjugate
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
July 2020: diversity and inclusion in clinical trials round-up
The shocking stats surrounding black women and health outcomes. Alarmingly, although black women are overall less likely to develop breast cancer, they’re 40% more likely to die from it compared ... Black women are at higher risk for a type of
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
cell carcinoma, Merkel cell carcinoma, and triple-negative breast cancer (TNBC) via chest-wall lesions.8. ... 2018; 15(10):599-616. National Cancer Institute. Surveillance, Epidemiology, and End Results Program.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- Europe’s cancer community publishes new report on transforming patient care
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- EU outlines measures to mitigate antibiotic shortage across Europe
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Merging global and local pharmacovigilance operations into a successful integrated approach
PMHub
Origins - The Patient Focused Specialists
Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
